Israel’s BrainStorm says stem cell drug benefits most patients in ALS trial – Reuters
|
Israel's BrainStorm says stem cell drug benefits most patients in ALS trial
Reuters Shares in the company, which is also developing stem cell treatments for multiple sclerosis and Parkinson's disease, have nearly doubled in the past two sessions on Nasdaq in anticipation of the trial's results. The stock has nearly tripled in the past … BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly … |
